Darolutamide Patent Expiration
Darolutamide is Used for treating non-metastatic castration-resistant prostate cancer. It was first introduced by Bayer Healthcare Pharmaceuticals Inc
Darolutamide Patents
Given below is the list of patents protecting Darolutamide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Nubeqa | US10010530 | Carboxamide derivative and its diastereomers in stable crystalline form | Jan 28, 2036 | Bayer Healthcare |
| Nubeqa | US10383853 | Carboxamide derivative and its diastereomers in stable crystalline form | Jan 28, 2036 | Bayer Healthcare |
| Nubeqa | US10711013 | Androgen receptor modulating compounds | Oct 27, 2030 | Bayer Healthcare |
| Nubeqa | US10835515 | Carboxamide derivative and its diastereomers in stable crystalline form | Jan 28, 2036 | Bayer Healthcare |
| Nubeqa | US11046713 | Androgen receptor modulating compounds | Oct 27, 2030 | Bayer Healthcare |
| Nubeqa | US11168058 | Manufacture of a crystalline pharmaceutical product | Feb 27, 2038 | Bayer Healthcare |
| Nubeqa | US8975254 | Androgen receptor modulating compounds | Mar 25, 2033 | Bayer Healthcare |
| Nubeqa | US9657003 | Androgen receptor modulating compounds | Oct 27, 2030 | Bayer Healthcare |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳